ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

Susan Bernstein  |  December 18, 2018

Varicella-zoster-virus (VZV) reactivation, which can cause patients to develop herpes zoster (i.e., shingles), occurs more frequently in patients with systemic vasculitis and systemic lupus erythematosus (SLE) who have received intravenous cyclophosphamide than in otherwise healthy adults, according to a retrospective study published in The Journal of Rheumatology by researchers in France.1 The study also shows…

Filed under:ConditionsResearch RheumSystemic Lupus ErythematosusVasculitis Tagged with:cyclophosphamideherpes zostershinglesvalacyclovir

The Streets of Heaven: Remembering Nadia Morgan, MBBS

Philip Seo, MD, MHS  |  December 17, 2018

Editor’s notes: A memorial service for Nadia is being planned for Jan. 16, 2019, from 4:30-6:00 p.m. at Johns Hopkins Bayview Asthma and Allergy Center, Richard A. Grossi Auditorium, 5301 Hopkins Bayview Circle, Baltimore. To honor her life and the impact she made on the Division of Rheumatology, Johns Hopkins is establishing the Dr. Nadia D….

Filed under:Profiles Tagged with:Nadia Morganobituary

Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

Kurt Ullman  |  December 17, 2018

Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The…

Filed under:Research RheumVasculitis Tagged with:ANCA-Associated VasculitisMAINRITSAN2maintenancerituximab

psoriatic arthritis hand photo

New PsA Guideline Released

Kathy Holliman  |  December 17, 2018

The ACR & the National Psoriasis Foundation (NPF) have published a joint Guideline for the Treatment of Psoriatic Arthritis (PsA). The guideline will serve as an aid to practitioners managing active PsA in patients.

Filed under:Clinical Criteria/GuidelinesConditionsPsoriatic Arthritis Tagged with:first-line use of a TNFiJoint Guideline for the Treatment of Psoriatic Arthritis (PsA)National Psoriasis Foundation (NPF)oral small molecule (OSM) drugsPsA Resource Centerpsoriatic arthritisTNFi biologic

Can Integrated Care Lead to Better Outcomes?

Can Integrated Care Lead to Better Outcomes?

Shikha Mittoo, MD, MHS, FRCPC  |  December 17, 2018

A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…

Filed under:Conditions Tagged with:Association of Rheumatology Professionals (ARP)Integrated Careinterdisciplinarymultidisciplinary care

Long-Term Data Show Baricitinib Is Safe & Effective for RA

Michele B. Kaufman, PharmD, BCGP  |  December 17, 2018

Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…

Filed under:Drug Updates Tagged with:baricitinibRheumatoid Arthritis (RA)

Arthralgias in Children: What to Do When Kids Present with Joint Pain

Susan Bernstein  |  December 17, 2018

The evaluation of a child with arthralgia who has a normal physical examination provides a challenge to rheumatologists. Here are some insights into assessing and treating children with musculoskeletal pain syndromes…

Filed under:ConditionsPediatric Conditions Tagged with:arthralgiasChildrenPainPediatric

Big Data Drives New Research

Susan Bernstein  |  December 12, 2018

Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…

Filed under:Research RheumTechnology Tagged with:big dataelectronic health record (EHR)Research

Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Michele B. Kaufman, PharmD, BCGP  |  December 10, 2018

In a study, RA patients taking upadactinib monotherapy experienced less pain and morning joint stiffness than methotrexate-treated patients…

Filed under:Drug Updates Tagged with:ACTPenautoinjectorMethotrexatemonotherapyRheumatoid Arthritis (RA)tocilizumabupadacitinib

MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

Lara C. Pullen, PhD  |  December 10, 2018

New research has linked the risk of developing interstitial lung disease in rheumatoid arthritis patients with the promoter variant in MUC5B, which may also contribute to the development of idiopathic pulmonary fibrosis and an unsual interstitial pneumonia seen by high-resolution CT scan…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ILDInterstitial Lung DiseaseMUC5BRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 143
  • 144
  • 145
  • 146
  • 147
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences